New Model for Predicting Cancer Outcomes

Predicting the long-term outcomes and risk of progression in patients with cancer is an important component of care that can drive treatment strategies. Unfortunately, current risk prediction models are lacking and focus primarily on pretreatment factors such as tumor phenotype and patient characteristics, which are not always indicative of long-term outcome. The need for improved […]

Read More

Immunotherapy-saves-world-prIME-LINES

Encorafenib Plus Cetuximab and Binimetinib Improves OS in BRAF Mutant CRC

Approximately 10% to 15% of patients with metastatic colorectal cancer (mCRC) carry BRAF V600E mutations, which are associated with a poor prognosis and limited treatment options. Treatment with BRAF inhibitors has historically been ineffective due to multiple feedback mechanisms present in the MAP kinase pathway, leading to resistance. In other tumor types, combination of BRAF […]

Read More

fda-approvals-june-2019

FDA Issues Four Oncology/Hematology Approvals in June

Two New Indications for Pembrolizumab. The FDA extended the indication of the PD-1 inhibitor pembrolizumab (Keytruda®, Merck) to include its use as a first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) and for the treatment of patients with metastatic small cell lung cancer (SCLC) who have disease progression after at […]

Read More

Daratumumab-VTd Combo, a New Option For Transplant Eligible Myeloma

The majority of patients with newly diagnosed multiple myeloma (NDMM) are treated with induction therapy followed by autologous stem cell transplant (ASCT) and consolidation therapy. The combination of bortezomib, thalidomide, and dexamethasone (VTd) is one of the standard induction/consolidation regimens. Daratumumab, a CD38-targeting antibody, is effective as monotherapy and in combinations in relapsed or refractory […]

Read More

Lenalidomide Can Prevent Development of Symptomatic Multiple Myeloma

Smoldering multiple myeloma (SMM) is a heterogeneous disease. While observation is often sufficient for patients with low-risk disease, those with high-risk characteristics are more likely to develop symptomatic multiple myeloma (MM) and have poor outcomes. Early intervention in patients with high-risk disease may be an effective strategy to improve outcomes in this population. This was […]

Read More

Promising Targeted Therapies for Hard-to-Treat Molecularly Driven NSCLC

Targeted therapy is currently the preferred treatment approach for patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR, ALK, ROS1, BRAF, and NTRK alterations, while immune checkpoint inhibitors with or without chemotherapy are the standard of care for patients without these mutations. In recent years, new actionable targets in NSCLC have been uncovered and […]

Read More

Enfortumab Vedotin Active in Advanced Pretreated Urothelial Carcinoma

Cisplatin-based combination chemotherapy is the standard first-line therapy for patients with metastatic urothelial cancer (UC). Patients with high PD-L1 expression who are not eligible for platinum chemotherapy may receive first-line treatment with immune checkpoint inhibitors, pembrolizumab or atezolizumab. Following progression on platinum-based chemotherapy, most patients are treated with one of the five PD-(L)1 inhibitors currently […]

Read More

Chemotherapy-Free Regimen for Platinum-Sensitive Ovarian Cancer

Platinum-based chemotherapy followed by poly(ADP-ribose) polymerase (PARP) inhibitor maintenance is the established standard of care for platinum-sensitive recurrent ovarian cancer. However, use of platinum-based chemotherapy is limited due to risk of cumulative toxicity. The PARP inhibitor niraparib has demonstrated efficacy both as maintenance therapy following platinum chemotherapy (NOVA trial) and as a monotherapy in pretreated […]

Read More

Ribociclib/ET Combo Extends Survival in Premenopausal Breast Cancer

For patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, combination therapy with a cyclin-dependent kinase (CDK) 4/6 inhibitor and endocrine therapy (ET) is standard first-line therapy for both postmenopausal and premenopausal patients based on substantial improvement of progression-free survival (PFS) in randomized phase III trials. However, significant improvement […]

Read More

Maintenance Olaparib Prolongs PFS in BRCA-Mutated Pancreatic Cancer

The prognosis of patients with metastatic pancreatic cancer (mPCA) remains poor, despite use of modern chemotherapy regimens such as FOLFIRINOX and nab-paclitaxel/gemcitabine. After progression on frontline therapy, less than half of the patients are eligible for second-line treatment. There is a high, unmet need for targeted biomarker selected treatment approaches. In ovarian and breast cancer, […]

Read More